The use of growth hormone (GH) for children with growth hormone deficiency
(CHD) is well established, However, GHD is a syndrome that affects patients
of all ages. Literature on pediatric GHD is extensive because treatment of
this condition with recombinant GH replacement was approved about 12 years
ago. Although GH-replacement therapy for adult GHD has been accepted pract
ice in Europe for nearly 15 years, it was approved only recently for this i
ndication in the United States, In adults, GHD has nonspecific symptoms, su
ch as fatigue and impaired psychointellectual capacities, or no symptoms. Q
uantifiable alterations induced by GHD in adults may include altered body c
omposition, reduced bone mineral density, impaired physical performance, ab
normal lipid metabolism, and impaired quality of life. Appropriate patient
selection for laboratory testing to confirm GHD is important because of the
expense, difficulties, and risk inherent: in its biochemical diagnosis. GH
D is common in patients with treated or untreated pituitary tumors or other
disorders of the pituitary, patients who have had cranial irradiation, and
adults with a history of childhood-onset GHD, Isolated low levels of insul
in-like growth factor-1 may indicate GHD but cannot substitute for an inade
quate response of serum GH to insulin induced hypoglycemia or another GH se
cretagogue.